HIGHLIGHTS
- What: Our analysis suggests that while both fresolimumab and tocilizumab are likely effective in reducing systemic sclerosis disease activity, fresolimumab did so by more than nine times that of the tocilizumab-treated group.
- Who: Sultan Akbar from the ATStill University, School of Osteopathic Medicine in Arizona (ATSU-SOMA). have published the research: Pharmacotherapy of Systemic Sclerosis: A Comparison of Skin Score with Fresolimumab and Tocilizumab, in the Journal: (JOURNAL)
- Future: For this review seemed to have a greater reduction of disease activity than did Further studies with greater sample sizes are needed to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.